{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:58:29Z","timestamp":1792425509396,"version":"4.5.0"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,7,14]]},"published-print":{"date-parts":[[2025,10]]},"DOI":"10.2967\/jnumed.125.270318","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T14:15:18Z","timestamp":1755785718000},"page":"1631-1638","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating Radiotheranostic Targets for Endometrial Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Joni","family":"Sebastiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane A.","family":"McGlone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary V.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugar","family":"Galka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Colaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Zeglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2025100106250822000_66.10.1631.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00323-3"},{"key":"2025100106250822000_66.10.1631.2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3390\/cancers14081922","article-title":"Endometrial cancer management in young women","volume":"14","author":"Markowska","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025100106250822000_66.10.1631.3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/diagnostics14040417","article-title":"Racioethnic disparities in endometrial cancer outcomes","volume":"14","author":"Illah","year":"2024","journal-title":"Diagnostics (Basel)."},{"key":"2025100106250822000_66.10.1631.4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/cancers15041091","article-title":"Management of patients diagnosed with endometrial cancer: comparison of guidelines","volume":"15","author":"Restaino","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2025100106250822000_66.10.1631.5","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3390\/ijms19082380","article-title":"Targeted therapies in type II endometrial cancers: too little, but not too late","volume":"19","author":"Remmerie","year":"2018","journal-title":"Int J Mol Sci."},{"key":"2025100106250822000_66.10.1631.6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ajog.2023.06.043","article-title":"Long-term outcomes of hysterectomy with bilateral salpingo-oophorectomy: a systematic review and meta-analysis","volume":"230","author":"Hassan","year":"2024","journal-title":"Am J Obstet Gynecol."},{"key":"2025100106250822000_66.10.1631.7","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/cancers13246275","article-title":"Recurrent endometrial cancer: local and systemic treatment options","volume":"13","author":"R\u00fctten","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025100106250822000_66.10.1631.8","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.3390\/curroncol30090574","article-title":"An overview of endometrial cancer with novel therapeutic strategies","volume":"30","author":"Kuhn","year":"2023","journal-title":"Curr Oncol."},{"key":"2025100106250822000_66.10.1631.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1736"},{"key":"2025100106250822000_66.10.1631.10","first-page":"e65638","article-title":"The role of immunotherapy in the treatment of gynecologic cancers: a systematic review","volume":"16","author":"Farajimakin","year":"2024","journal-title":"Cureus."},{"key":"2025100106250822000_66.10.1631.11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40487-024-00308-0","article-title":"A narrative review of the clinical, humanistic, and economic value of pembrolizumab-based immunotherapy for the treatment of breast and gynecologic cancers","volume":"12","author":"Monberg","year":"2024","journal-title":"Oncol Ther."},{"key":"2025100106250822000_66.10.1631.12","doi-asserted-by":"crossref","unstructured":"Bodei L Lewis J Zeglis BM . Radiopharmaceutical Therapy. Springer; 2023.","DOI":"10.1007\/978-3-031-39005-0"},{"key":"2025100106250822000_66.10.1631.13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-24-1007","article-title":"Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial","volume":"31","author":"Rediti","year":"2025","journal-title":"Clin Cancer Res."},{"key":"2025100106250822000_66.10.1631.14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"key":"2025100106250822000_66.10.1631.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0558-y"},{"key":"2025100106250822000_66.10.1631.16","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2009.119"},{"key":"2025100106250822000_66.10.1631.17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw401"},{"key":"2025100106250822000_66.10.1631.18","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.3390\/biomedicines11123159","article-title":"Targeting CD24 in cancer immunotherapy","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines."},{"key":"2025100106250822000_66.10.1631.19","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/jcm9061900","article-title":"Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis","volume":"9","author":"Coll-de la Rubia","year":"2020","journal-title":"J Clin Med."},{"key":"2025100106250822000_66.10.1631.20","first-page":"52521","article-title":"The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies","volume":"96","author":"Zeglis","year":"2015","journal-title":"J Vis Exp."},{"key":"2025100106250822000_66.10.1631.21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11307-024-01898-x","article-title":"MIB guides: measuring the immunoreactivity of radioimmunoconjugates","volume":"26","author":"Delaney","year":"2024","journal-title":"Mol Imaging Biol."},{"key":"2025100106250822000_66.10.1631.22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jso.27552","article-title":"Moving into the modern era of molecular classification for endometrial cancer","volume":"129","author":"Dagher","year":"2024","journal-title":"J Surg Oncol."},{"key":"2025100106250822000_66.10.1631.23","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.3390\/ijms25147742","article-title":"Tailoring endometrial cancer treatment based on molecular pathology: current status and possible impacts on systemic and local treatment","volume":"25","author":"Ribeiro-Santos","year":"2024","journal-title":"Int J Mol Sci."},{"key":"2025100106250822000_66.10.1631.24","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1021\/acsptsci.4c00275","article-title":"Exploring the interplay between radioimmunoconjugates and Fc\u03b3 receptors in genetically engineered mouse models of cancer","volume":"7","author":"Rodriguez","year":"2024","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2025100106250822000_66.10.1631.25","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.3390\/ijms25179659","article-title":"Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in malignant solid tumors","volume":"25","author":"Pavelescu","year":"2024","journal-title":"Int J Mol Sci."},{"key":"2025100106250822000_66.10.1631.26","first-page":"104665","article-title":"Enhertu (Fam-trastuzumab-deruxtecan-nxki)\u2014revolutionizing treatment paradigm for HER2-low breast cancer","volume":"82","author":"Siddiqui","year":"2022","journal-title":"Ann Med Surg (Lond)."},{"key":"2025100106250822000_66.10.1631.27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000533866","article-title":"The potential of trastuzumab deruxtecan as a tissue agnostic drug","volume":"101","author":"J\u00f8rgensen","year":"2023","journal-title":"Oncology."},{"key":"2025100106250822000_66.10.1631.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266392"},{"key":"2025100106250822000_66.10.1631.29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/jpm10040255","article-title":"The emerging role of CD24 in cancer theranostics\u2014a novel target for fluorescence image-guided surgery in ovarian cancer and beyond","volume":"10","author":"Kleinmanns","year":"2020","journal-title":"J Pers Med."},{"key":"2025100106250822000_66.10.1631.30","first-page":"482","article-title":"ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking \u201cdon\u2019t-eat-me\u201d signal [abstract]","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer."},{"key":"2025100106250822000_66.10.1631.31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med."},{"key":"2025100106250822000_66.10.1631.32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/BD-1999-11111","article-title":"Anti-HER2 radioimmunotherapy","volume":"11","author":"Brechbiel","year":"2000","journal-title":"Breast Dis."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:25:27Z","timestamp":1759325127000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.2967\/jnumed.125.270318"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270318","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}